Murphy and co-workers highlight especially three genes of interest in their genome-wide analyses (FGFR2, MAT1A and CASP1) that vary between 2 % and 5 % in methylation between mild and advanced NAFLD cases [13]. The gene discussed is FGFR2; the disease is metabolic dysfunction-associated steatotic liver disease.